About MAIA Biotechnology, Inc. MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of ...

PDS Biotechnology ( ($PDSB) ) has shared an update. On June 2, 2025, PDS Biotechnology Corporation announced the publication of three Versamune® ...

Poster presentation to highlight the ongoing global Phase 3 ASP-1929-381 study at ASCO 2025Global patient enrollment continues, with Taiwan now actively enrolling following the U.S., and Japan ...

CytoDyn Inc. VANCOUVER, Washington, May 15, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with ...

Pelareorep initiates a pro-inflammatory tumor microenvironment (TME) and induces innate and adaptive immune responses New ...

MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage ... for THIO treatment was selected for poster presentation at the European Lung Cancer Congress ...

REHOVOT, Israel, March 28, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (PPBT) ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company ...

BioAtla, Inc., a biotechnology company specializing in Condition Active Biologic (CAB) antibody therapeutics for solid tumors, announced it will present a poster at the upcoming 2025 ASCO Annual ...

Poster highlights potential predictive biomarker for therapeutic response in advanced non-small cell lung cancer (NSCLC) MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA", the "Company"), a ...